Key Takeaways:
- Petrelintide achieved up to 10.7% mean weight loss at week 42 in Phase 2 trial
- Only 1.5% of patients discontinued due to gastrointestinal adverse events
- Phase 3 trials for chronic weight management planned for H2 2026
Back
Zealand Pharma's petrelintide delivers 10.7% weight loss with placebo-like tolerability
Zealand Pharma A/S (Nasdaq: ZEAL) said its experimental amylin analog petrelintide achieved up to 10.7% mean weight loss at 42 weeks in a Phase 2 trial, with gastrointestinal side effects comparable to placebo and only 1.5% of patients discontinuing due to GI issues.
"As we continue to advance the field of obesity medicine, expanding the therapeutic options beyond the current single class of treatments is critical," Prof. W. Timothy Garvey, MD, Department of Nutrition Sciences at the University of Alabama at Birmingham, said in a statement. "These data highlight the potential of petrelintide to be just such a treatment — effective and well-tolerated with the potential to facilitate long-term obesity therapy."
The ZUPREME-1 trial randomized 485 adults with a mean body weight of 107.1 kilograms and BMI of 36.7 to five doses of once-weekly petrelintide or placebo. Patients on petrelintide lost up to 10.7% of body weight from baseline at week 42, compared with 1.7% for placebo. Nausea was the most common GI adverse event, reported for 19.6% of petrelintide patients versus 6.2% on placebo, while vomiting occurred in 3% of the treatment group versus 6.2% on placebo. Between 88% and 98% of patients successfully escalated to their target maintenance dose.
The data positions petrelintide as a potential differentiator in the obesity market, where GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound dominate but carry GI tolerability challenges that drive discontinuation. Zealand and partner Roche plan to initiate Phase 3 trials for chronic weight management in the second half of 2026, setting up a pivotal catalyst for the Danish biotech.
Tolerability Profile Stands Out
The low discontinuation rate of 1.5% due to GI adverse events compares favorably with GLP-1 class drugs, where nausea and vomiting are leading causes of treatment dropout. Most GI events reported were mild, and rates of diarrhea and constipation were similarly low between groups. The placebo-like tolerability could support long-term treatment persistence, a key challenge in obesity care where patients often stop therapy within a year.
Cardiometabolic Improvements
Beyond weight loss, petrelintide showed meaningful improvements in cardiovascular risk markers. Waist circumference decreased by 7.9 to 10.8 centimeters versus 4.3 centimeters for placebo. High-sensitivity C-reactive protein, a marker of inflammation, fell by 17% to 41% compared with 6% for placebo. Triglycerides dropped by 12% to 21% versus 9% for placebo.
The results were presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans on June 5. Full data from the ZUPREME-1 trial are expected to be published later this year.
The positive readout strengthens Zealand's position in the obesity market, which Goldman Sachs estimates could reach $130 billion by 2030. Investors will watch for Phase 3 initiation details in the second half of 2026 as the next catalyst for ZEAL shares.
This article is for informational purposes only and does not constitute investment advice.
[1] New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity[2] New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management ...[3] Zealand touts promising tolerability data for obesity drug in mid-stage study[4] An Experimental Weight Loss Drug Could Outperform Ozempic. Here's What Makes It Different.
© 2026 Edgen Powered by